65,437 trials
Asthma
Primary: Difference Between Number of Families Who Adopted MyAsthma Portal Use and Number of Families With Sustained Use — 156; 81 participants
Developmental Delays
Primary: Difference in the Number of Participants Who Completed Early Intervention Intake and Evaluation Visits Between Treatment Groups — 20; 21; 17; 17 participants
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Primary: Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 — 79.1; 80.6 percentage of participants
Influenza
Primary: Humoral Immune Response for Each Vaccine Strain in Terms of Haemagglutination Inhibition (HI) Antibody Titers. — 47.3; 31.2; 460.2; 166.9 Titers
Late Effects of Surgery · Staphylococcus Aureus · Surgical Site Infection
Primary: Mean Daptomycin Concentrations at 12, 18, 24, and 48 h — 22.7; 16.2; 12.0; 3.5 mcg/ml
Osteoarthritis
Primary: Change From Baseline in Quadriceps Central Activation Ratio at 12 Weeks — 0.01; -0.04 unitless
Heart Failure
Primary: AV Interval Determination Using Impedance — 14 participants
Rheumatoid Arthritis
Primary: Percentage of Participants With an Adverse Event (AE) — 83 percentage of participants
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% Response Criteria (ACR20) — 78.1; 80.5 percentage of participants
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% Response Criteria (ACR20) — 64.1; 66.0 percentage of participants
Acute Stroke
Primary: Safety — 0 participants
Pain
Primary: Time to Significant Increase in Local Surface Temperature
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Pancreatic Cancer
Primary: Overall Survival — 136.5; 129.5 days — p=0.0494
Malignant Solid Tumor
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab — 277; 315 microgram/milliliter (ug/mL)